Cuu Long Pharmaceutical Joint Stock Company (DCL) respectfully informs the competent authorities, valued customers, partners, and all individuals concerned about the product Projoint 750 of the following:
On September 29, 2025, the Hanoi Department of Health officially issued Official Dispatch No. 5180/SYT-NVD, recognizing that the drug sample Projoint 750 (Glucosamine sulfate 750 mg, Registration No.: VD-20684-14, Batch No.: 01210524, Mfg. Date: 21/05/2024, Exp. Date: 21/05/2027), manufactured by Cuulong Pharmaceutical Joint Stock Company, meets the quality requirement for the parameter “Dissolution” in accordance with the standard provided by the Drug Administration of Vietnam (DAV).
At the same time, the Department revoked Official Dispatch No. 4133/SYT-NVD dated August 11, 2025, regarding the recall of the product Projoint 750 for failing to meet quality standards.
Previously, on August 29, 2025, the National Institute for Drug Quality Control (NIDQC) issued Official Document No. 1171/VKNTTW-KHTH, accompanied by Test Report No. 55L528 dated August 29, 2025, confirming the results of the supplementary testing and affirming that the drug sample Projoint 750 (Registration No.: VD-20684-14) meets the approved internal quality standards submitted to the regulatory authorities.
On September 9, 2025, the Drug Administration of Vietnam (DAV) issued Official Dispatch No. 2565/QLD-CL, concluding that the Projoint 750 sample complies with the required quality standards as prescribed.
The Projoint 750 (Glucosamine sulfate 750 mg) drug product manufactured by DCL has been officially reinstated to the market.
Based on the published investigation results, on September 10, 2025, Cuu Long Pharmaceutical Joint Stock Company issued Official Letter No. 373/CV.DCL to the Hanoi Department of Health, notifying that the drug product Projoint 750 (Glucosamine sulfate 750 mg, Registration No.: VD-20684-14, Batch No.: 01210524, Mfg. Date: 21/05/2024, Exp. Date: 21/05/2027) manufactured by the company had been confirmed to meet the required quality standards. The company also requested the Department to issue an amended document to revoke the validity of Official Dispatch No. 4133/SYT-NVD dated August 11, 2025, sent to relevant units, in order to ensure consistency and prevent any impact on the circulation and timely supply of the product to customers and partners.
After a period of careful review and verification, the Hanoi Department of Health agreed with Cuulong Pharmaceutical’s request and issued Official Dispatch No. 5180/SYT-NVD, confirming that Projoint 750 meets quality standards and lifting the recall order for the product.
Thus, after nearly three months (from August 7, 2025 to September 29, 2025) of scientific, transparent, and objective review and investigation with the participation of competent authorities, the product Projoint 750 (Glucosamine sulfate 750 mg, Registration No.: VD-20684-14, Batch No.: 01210524, Mfg. Date: 21/05/2024, Exp. Date: 21/05/2027) manufactured by Cuu Long Pharmaceutical Joint Stock Company has been officially confirmed to meet quality standards and approved for continued circulation in the market to promptly meet public demand.
This is truly good news for Cuu Long Pharmaceutical, as well as for its partners, customers, patients, and all those concerned about the product Projoint 750.
A representative of Cuu Long Pharmaceutical Joint Stock Company emphasized: “We strictly comply with all regulations of the Ministry of Health in the production, testing, and distribution of pharmaceutical products. The recent matter has been promptly, scientifically, and transparently clarified, reaffirming the high quality of Projoint 750. We sincerely appreciate the cooperation of regulatory authorities and the trust of consumers.”
As a reputable company with nearly 50 years of experience in the pharmaceutical industry, Cuu Long Pharmaceutical Joint Stock Company is always committed to cooperating and accompanying regulatory bodies and is ready to fulfill its responsibilities in accordance with the law whenever any issues arise concerning its brand.
Cuulong Pharmaceutical firmly believes that reputation is the most valuable asset of a business. Therefore, we continuously strive to ensure product quality, transparency, and accuracy in our management systems. We are fully committed to acting with responsibility, integrity, and determination to remain worthy of the trust of our customers, partners, and the community.
